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Abstract
l-Alpha-glycerylphosphorylcholine (GPC) is a widely used food supplement. GPC has been shown to exert beneficial 
effects in several organs; however, the cardiac effects of GPC have yet to be investigated. The aim of the present study was 
therefore to map out the effects of GPC on cardiac myocytes, with or without ischemia–reperfusion insult. Neonatal rat 
cardiac myocytes were treated with GPC at 1, 10, 80, and 100 µM concentrations for 15 min, 3 h, or 24 h, respectively. Cell 
viability by calcein assay and the degree of oxidative stress by DHE (superoxide level) and  H2DCF (total ROS accumulation) 
staining were measured. In separate experiments, cardiomyocytes were pre-treated with the optimal concentration of GPC 
for 3 h and then cells were exposed to 4 h of simulated ischemia followed by 2 h of reperfusion (SI/R). Cell viability was 
measured at the end of the SI/R protocol. In normoxic conditions, the 15-min and the 3-h GPC treatment did not affect cell 
viability, total ROS, and superoxide levels. Under SI/R conditions, the 3-h GPC treatment protected the cardiac myocytes 
from SI/R-induced cell death and did not alter the level of oxidative stress. The 24-h GPC treatment in normoxic conditions 
resulted in significant cell death and increased oxidative stress at each concentration. Here we provide the first evidence for 
the cytoprotective effect of short-term GPC treatment. However, long-term administration of GPC may exert cytotoxicity in 
a wide concentration range in cardiac myocytes. These results may draw attention to a comprehensive cardiac safety protocol 
for the testing of GPC.
Keywords Neonatal rat cardiac myocytes · l-Alpha-glycerylphosphorylcholine · Mitochondrial dysfunction · Oxidative 
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Introduction
l-Alpha-glycerylphosphorylcholine (choline alphoscerate, 
GPC) is a natural endogenously produced choline deriva-
tive and acetylcholine precursor in the brain which (in the 
form of a synthetic compound) is widely used as a food 
supplement [1]. After oral ingestion, it is converted meta-
bolically to phosphatidylcholine, the active form of cho-
line that is able to increase acetylcholine levels in the brain 
[2–4]. In terms of its use as a food/health supplement, 
oral GPC intake/supplementation has gained growing 
attention in both the media and in scientific areas. Since 
1998, the Institute of Medicine of the National Academy 
of Sciences (USA) has recognized choline as an essen-
tial nutrient for humans and has made recommendations 
for the dietary choline intake (Institute of Medicine and 
National Academy of Sciences 1998). It has been shown 
that GPC supplements may help substitute for insufficient 
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dietary choline [5]. GPC also contributes to the synthesis 
of membrane phospho- and glycerolipids, and thus posi-
tively influences membrane fluidity [4, 6].
GPC is generally considered a safe and non-toxic com-
pound [4] and it is classified as GRAS (Generally recognized 
as safe) in the USA (GRN 000419). In Italy and Poland, 
GPC is a registered drug (Anatomical Therapeutic Chemi-
cal Classification System code: n07ax02) marketed under 
the trade name Gliatilin (produced by Italfarmaco S.p.A., 
Milan; Italy). It is recommended for use in humans to sup-
port brain health and mental capacity. A multicentric, clini-
cal trial confirmed the therapeutic role of alpha-GPC on the 
cognitive recovery of patients with acute stroke or transient 
ischemic attack [7]. Along this line, GPC was shown to exert 
neuroprotective effects in some mental disorders in a series 
of human clinical studies [8–11].
In addition to its neuroprotective effects, GPC was docu-
mented to preserve mitochondrial respiration in liver mito-
chondria and to reduce hepatic ischemia-induced oxidative 
stress and inflammation in rodent models of ischemia/rep-
erfusion (I/R) [12, 13]. Protective effects of GPC associated 
with reduced radical production have been documented also 
in a relevant rodent model of mesenteric I/R [14]. In view 
of this, we hypothesized that GPC could prevent oxidative 
damage following I/R insult in other tissues, including the 
myocardium.
One concern of GPC is determining the correct dosage, as 
it is reported that inadequate intake or abnormal metabolism 
of choline is associated with the increased risk of cardiovas-
cular disease and various cancers [15, 16]. Dose–response 
experiments were so far restricted to the brain. To the best 
of our knowledge, the cardiac effects of GPC have yet to be 
examined.
Therefore, the major objective of the present study was to 
evaluate the timing and doses of GPC treatment on isolated 
cultured cardiac myocytes, with a special focus on observ-
ing the effects of GPC on the degree of oxidative stress. 
We aimed to test the hypothesis that GPC could prevent 
ischemia-induced cell death and oxidative stress in cardiac 
myocytes subjected to simulated I/R.
Materials and methods
Our experiments were performed in accordance with the 
EU directive guidelines for the care and use of laboratory 
animals, published by the European Union (2010/63/EU). 
Methods were also reviewed by the National Scientific 
Ethical Committee on Animal Experimentation (National 
Competent Authority of Hungary) and were approved by 
the Animal Welfare Committee of the University of Szeged 
(I-74-52/2012 MAB).
Culturing primary neonatal rat cardiac myocytes
Neonatal rat cardiac myocytes (NRCMs) were isolated 
from newborn Wistar rats using the previously described 
method [17]. The neonatal rats were sacrificed by cervi-
cal dislocation. The hearts were rapidly removed and then 
placed into a cold (+ 4 °C) phosphate buffered saline (PBS) 
solution. After the separation of atria, the ventricles were 
minced with fine forceps and then collected in 0.25% trypsin 
(Gibco BRL). Tissue fragments were further digested by 
trypsin for 25 min in a Falcon tube in a 37 °C water bath. 
Then the cell suspension was centrifuged (450×g for 15 min 
at 4 °C). Afterwards, the cell pellet was re-suspended in 
culture medium—Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 
l-Glutamine, and AB/AM (Sigma). The single cell suspen-
sion was pre-plated in six-well plates at 37 °C for 90 min to 
enrich the culture with cardiac myocytes. The non-adherent 
myocytes were collected and plated at a density of  104 cells/
well onto 96-well plates. The culture medium was changed 
the day after preparation to a 1% FBS containing prolifera-
tion medium. The cells were maintained at 37 °C in a stand-
ard  CO2 incubator (Humidified atmosphere of 5%  CO2).
Experimental groups
The concentration-dependent influence of GPC on cell 
viability and the degree of oxidative stress were tested in 
3-day-old primary rat cardiac myocyte cultures exposed to 
acute (15 min), short-term (3 h), and long-term (24 h) GPC 
treatment in the 1–100 µM concentration range under nor-
moxic conditions (n = 8–16) (Fig. 1a). One group of cells 
was pre-treated with GPC for 3 h and then subjected to simu-
lated ischemia/reperfusion (SI/R). During the entire proto-
col, the GPC concentration range (1–100 µM) was sustained 
(Fig. 1b). In all experiments, GPC was dissolved in physi-
ological saline, while the Vehicle group was treated with 
physiological saline solution alone in 0.1 v/v%. 2–3 isolation 
rounds were performed for each experimental series and data 
of all individual wells were analyzed.
Simulated ischemia/reperfusion (SI/R)
To simulate ischemic conditions, the culture medium was 
replaced with a hypoxic solution containing in mM: NaCl 
119, KCl 5.4,  MgSO4 1.3,  NaH2PO4 1.2, HEPES 5,  MgCl2 
0.5,  CaCl2 0.9, Na-lactate 20, BSA 0.1% pH 6.4. To induce 
hypoxia, the cells were then placed into a three-gas incuba-
tor, gassed through with a mixture of 95%  N2 and 5%  CO2 
for 4 h at 37 °C (simulated ischemia). Normoxic control 
cells were then covered with normoxic solution contain-
ing in mM: NaCl 125, KCl 5.4,  NaH2PO4 1.2,  MgCl2 0.5, 
HEPES 20,  MgSO4, 1.3,  CaCl2 1, glucose 15, taurine 5, 
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creatine-monohydrate 2.5 and BSA 0.1%, pH 7.4 and cells 
were kept in normoxic incubator. After simulated ischemia 
or normoxia, the cells were placed to normoxic incubator; 
hypoxic or normoxic medium was then replaced by culture 
medium (simulated reperfusion) for 2 h at 37 °C.
Cell viability assay
Cell viability was assessed by a calcein assay performed 
at the end of each experimental protocol. In this assay, the 
cell-permeant calcein-AM dye stains living cells which are 
then converted to green-fluorescent calcein by intracellular 
non-specific esterases. The medium was removed, and then 
the cells were washed with PBS twice and incubated with 
calcein (1 μM) dissolved in DMSO and further diluted 
in D-PBS (containing Ca and Mg) for 30 min in a dark 
chamber. Following this, the calcein solution was replaced 
with fresh PBS and the fluorescence intensity of each 
well was measured by a fluorescent plate reader (FluoStar 
Optima, BMG Labtech) in a well scanning mode (Scan 
matrix: 10 × 10; scan diameter: 10 mm; bottom optic; no of 
flashes/scan point: 3; temp: 37 °C; excitation wavelength: 
490 nm; emission wavelength: 520 nm).
Oxidative stress measurements
The level of superoxide  (O2−) was measured at the end 
of the experimental protocol by dihydroethidium (DHE) 
staining, which can visualize the amount of superoxide 
present in the cells. DHE exhibits blue fluorescence in the 
cytoplasm and upon oxidation, it intercalates into the DNA 
and switches to a bright red fluorescence. The fluorescent 
intensity of each well was detected by a fluorescent plate 
reader (FluoStar Optima, BMG Labtech) in a well scan-
ning mode (scan matrix: 10 × 10; scan diameter: 10 mm; 
bottom optic; no of flashes/scan point: 3; temp: 37 °C; 
excitation wavelength: 530  nm; emission wavelength: 
620 nm).
The total reactive oxygen species (ROS) content was 
measured by cell-permeant 2′-7′-dichlorodihydrofluores-
cein diacetate  (H2DCFDA), which is a chemically reduced 
form of fluorescein and used as an indicator of ROS level 
in cells. Upon cleavage of the acetate groups by intracellu-
lar esterases and oxidation, the non-fluorescent  H2DCFDA 
is converted to the highly fluorescent 2′-7′-dichlorofluo-
rescein (DCF). The fluorescent intensity of each well 
was detected later by a fluorescent plate reader (FluoStar 
Optima, BMG Labtech) in a well scanning mode (scan 
matrix: 10 × 10; scan diameter: 10 mm; bottom optic; no of 
flashes/scan point: 3; temp: 37 °C; excitation wavelength: 
480 nm; emission wavelength: 520 nm).
Statistical analysis
Results are expressed as mean ± SEM. One-way analysis 
of variance (ANOVA) followed by Dunnett’s multiple 
comparison post hoc tests were used to analyze differences 
in mean values of the experimental groups versus vehicle. 
Differences were considered significant at p < 0.05.
Results
Acute effect of GPC in isolated NRCMs in normoxic 
conditions
In normoxic conditions, the acute (15 min) treatment with 
different concentrations of GPC had no impact on the cell 
viability of NRCMs in comparison to the vehicle control 
a
2h 
reoxygenaon
Normoxia experimental protocol
1% FBS
Viability (calcein), superoxid (DHE), 
total ROS (H2DCF) measurement
Neonatal cardiomyocytes isolaon
GPC treatment
10% FBS
24h GPC
3h GPC
15min GPC
yad3yad2yad1yad0
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0 day              1 day 2 day Normoxia 3 day
4h 
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b
Simulated Ischemia/Reoxygenaon experimental protocol
3h pre  +     4h SI      +    2h R = 9h GPC
Fig. 1  Experimental protocol: after the isolation of the neonatal rat 
cardiomyocytes (NRCMs) from newborn Wistar rats, the cells were 
then cultured in a 10% FBS containing medium for 24  h. After the 
first day, the cells were kept in a 1% FBS containing medium. a Glyc-
erophosphorylcholine (GPC) treatment was applied under normoxic 
conditions. Three series of cells were treated at day 3 with GPC for 
15 min, 3 h, or 24 h, respectively, all prior to cell viability measure-
ments. b GPC treatment was then applied 3 h prior to 4-h simulated 
ischemia (SI), and during the 2-h reperfusion period
 Molecular and Cellular Biochemistry
1 3
(Fig. 2a). Neither the extent of superoxide production nor 
total ROS accumulation changed significantly after 15-min 
exposure to GCP in cardiac myocytes (Fig. 2b, c). On the 
basis of our earlier findings by Strifler and co-workers [12], 
acute effects of GPC on mitochondrial respiration were also 
investigated in this setup, and interestingly, treatment with 
80–100 µM GPC heavily increased the oxygen consumption 
rate (OCR) of cardiac myocytes (Supplementary Fig. 2).
Short‑term effect of GPC in NRCMs in normoxic 
conditions
In normoxic conditions, similarly to those observations after 
acute administration, the short-term (3 h) GPC treatments 
did not change significantly the cell viability of NRCMs in 
comparison to the vehicle control (Fig. 3a).
In short-term applications of GPC, none of the applied 
concentrations had an influence on the superoxide level in 
cardiomyocytes (Fig. 3b). Nevertheless, a 3-h treatment with 
100 µM GPC resulted in a significant reduction of the over-
all ROS production compared to the vehicle-treated group 
(Fig. 3c). Taken together this surprising observation with 
the above-mentioned OCR results, we suggest a direct intra-
mitochondrial effect of exogenous GPC (as was noted in our 
previous study) between 80 and 100 µM concentration that 
was represented by a higher OCR and a subsequent physi-
ological mitochondrial ROS formation. It was possibly fol-
lowed by a general compensatory mechanism of the cells 
to scavenge the extended amount of ROS which was mani-
fested in a significant decrease at 100 µM treatment.
Effect of short‑term application of GPC in isolated 
NRCMs exposed to SI/R
To validate our SI/R model, first, the viability of cells 
exposed to simulated ischemia (hypoxic solution combined 
with hypoxic environment) was compared with that observed 
after the normoxia protocol (normoxic solution combined 
with normoxic environment). Those NRCMs which were 
encountered to the described SI/R protocol and challenged 
with either hypoxic solution or vehicle showed a signifi-
cant decline in cell viability in comparison to the normoxic 
group (Fig. 4a). Next, analysis of the degree of SI/R-caused 
reduction in cell viability was performed to compare the 
vehicle and the 3-h-long GPC pre-treated groups. Most of 
the applied concentrations of GPC had no effect on cell 
death. The 80 µM GPC pre-treatment, however, significantly 
improved cell viability after the SI/R challenge (Fig. 5a) and 
thereby rendered promising cytoprotective attribute.
In order to shed some lights on the antioxidant features of 
GPC in the chosen concentration range, superoxide produc-
tion and the overall ROS formation of the cardiac cells were 
both investigated under SI/R conditions. Interestingly, none 
of the applied GPC concentrations did result in significant 
changes in these two parameters (Fig. 5b, c), which suggests 
us that the cytoprotective effect of GPC might be other than 
direct ROS-scavenger capacity.
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Fig. 2  The acute effect of different concentrations of GPC on a 
cell viability b superoxide production and c total ROS produc-
tion in isolated NRCMs after 15  min of GPC treatment are shown. 
Results are normalized to vehicle-treated cells. Data are presented as 
mean ± S.E.M. Statistical analysis of data was performed by one-way 
ANOVA, followed by Dunnett’s multiple comparison test,*p < 0.05 
versus vehicle-treated cells (n = 8–16)
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Effect of long‑term GPC administration in isolated 
NRCMs in normoxic conditions
The long-term (24 h) GPC treatment of NRCMs induced 
profound cell death at each applied GPC concentration, as 
compared to the vehicle-treated group (Fig. 6a). In accord-
ance with these findings, the intracellular superoxide levels 
significantly increased at each applied concentration of GPC 
(Fig. 6b). Additionally, the overall ROS concentrations sig-
nificantly increased at 1 µM and 100 µM concentration of 
GPC (Fig. 6c) which might reflect some interesting crosstalk 
between mitochondrial and other intracellular ROS-scaven-
ger mechanisms.
Discussion
In our study, we sought to provide new pieces of evidence 
for the potential cardioprotective properties of GPC per se 
and under SI/R conditions. It has been increasingly recom-
mended to use as a nutraceutical compound. Finding a safe 
and beneficial therapeutic window for its application is cru-
cial. To date, no effects on cardiac tissue or cells of this 
compound are described. To confirm its biosafety, first, the 
normoxic experiments were carried out. Neither the acute, 
15-min nor the short-term, 3-h exposure to GPC affected the 
cell viability of neonatal rat cardiac myocytes. Nevertheless, 
significant, acute effects of GPC at 80–100 µM concentra-
tion were noted as regards mitochondrial respiration which 
was considered as a part of some physiological intra-mito-
chondrial ROS-producing mechanism that was in line with 
the short-term ROS reduction at 100 µM treatment. It is 
proposed that the cells might harbor compensatory increases 
in other ROS-scavenging mechanisms which are switched on 
in response to elevated mitochondrial respiration.
Next, SI/R challenge was performed to ascertain some 
protective potential of GPC. A 3-h treatment with 80 µM 
concentration of GPC had a cytoprotective effect as indi-
cated by the cell viability of cells challenged with SI/R. No 
significant changes were recorded regarding the pro-oxidant 
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Fig. 3  The short-term effect of different concentrations of GPC on a 
cell viability b superoxide production and c total ROS production in 
isolated NRCMs after 3 h of GPC treatment. Results are normalized 
to vehicle-treated cells. Data are presented as mean ± S.E.M. Statisti-
cal analysis of data was performed by one-way ANOVA, followed by 
Dunnett’s multiple comparison test,*p < 0.05 versus vehicle-treated 
cells (n = 8–16)
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Fig. 4  NRCMs which were encountered 4 h of simulated ischemia 
and 2 h reperfusion showed a significant decline in cell viabil-
ity in comparison to the normoxic group. Data are presented as 
mean ± S.E.M. Statistical analysis of data was performed by one-way 
ANOVA, followed by Dunnett’s multiple comparison test,*p < 0.05 
versus vehicle-treated cells (n = 8–16)
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parameters although a strong propensity for an increase in 
the total ROS level but not the superoxide quantity was con-
sidered at 80 and 100 µM GPC concentration.
Regarding the normoxic, 24-h experiments, long-term 
exposure to each GPC concentration in normoxic conditions 
resulted in extensive cellular death of the cardiac myocytes 
alongside with significantly increased overall ROS level at 
each applied concentration. To the best of our knowledge, 
this is the first demonstration of the potential cardiotoxic-
ity of GPC. We strongly recommend these findings to be 
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Fig. 5  The effect of 3-h pre-treatment of GPC in different concen-
trations on NRCM’s a viability b superoxide production and c total 
ROS production after 4 h of simulated ischemia and 2-h reperfusion. 
Results are normalized to normoxic control group. Data are pre-
sented as mean ± S.E.M. Statistical analysis of data was performed 
by one-way ANOVA, followed by Dunnett’s multiple comparison 
test,*p < 0.05 versus normoxic controls, #p < 0.05 versus vehicle-
treated cells (n = 8–16)
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Fig. 6  The long-term effect of different concentrations of GPC on a 
cell viability b superoxide production and c total ROS production in 
isolated NRCMs after 24 h of GPC treatment. Results are normalized 
to vehicle-treated cells. Data are presented as mean ± S.E.M. Statisti-
cal analysis of data was performed by one-way ANOVA, followed by 
Dunnett’s multiple comparison test,*p < 0.05 versus vehicle-treated 
cells (n = 8–16)
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taken into account and investigated in further details before 
designing clinical trials with chronic GPC administration 
in the future.
The most recent human study on high dosages of GPC 
examined the effects of a 6-day treatment on muscle strength 
[18], which showed limited effectiveness. According to the 
authors, there is a considerable issue with the current research 
on GPC because of the large variety in terms of dosage. Some 
studies examining GPC dosages up to 1000 mg (approx. 
4 mM) per se [1] and others describe a dosage within a nutri-
tional supplement range that was at a dose of 150 mg (approx. 
600 µM) [19]. There is a huge variation in the literature 
regarding acute versus long-term administration. The majority 
of studies used dosages of around 600 mg (approx. 2.4 mM) 
in an acute fashion, although the chronic dosing may vary 
heavily based on the health condition of the human subjects 
and could reach a daily dosage of 1000 mg for 28 days [7].
There is broad, reliable evidence for GPC tolerance in 
laboratory animals. Acute oral, as well as parenteral toxicity 
of GPC, has been shown to be very low in several animal spe-
cies including mice, rats, and dogs  (LD50 > 1000 mg/kg i.v./
i.p. in rodents;  LD50 > 500 mg/kg i.m. and  LD50 > 2000 mg/
kg p.o. in dogs). Additionally, sub-chronic and chronic oral 
toxicity of GPC is considered to be very low. A 4-week 
administration of 100 and 300 mg/kg GPC in rats did not 
alter behavior nor produce any signs of general toxicity. A 
26-week administration of 300 mg/kg GPC did not produce 
any toxic effects in rats and it showed only mildly reduced 
activity in dogs. A high dose of 1000 mg/kg induced reduced 
activity in rats [4]. In addition, GPC is considered not to be 
genotoxic both in vitro and in vivo: it exerts no mutagenicity 
in as high a dose as 3000 µg/mL of concentration in yeasts, 
and at 10.000 µg/plate concentration in bacterial colonies [4]. 
With respect to its toxicity, it should be pointed out that while 
GPC toxicity was tested mostly in vivo following oral admin-
istration [4], in the present study, we have tested the direct 
in vitro effects of GPC on neonatal rat cardiomyocyte cul-
tures. Since GPC is hydrolyzed in the gut mucosa [2], in vivo 
(after oral administration) and in vitro effects of GPC may 
differ. Nevertheless, cardiac toxicity and cardiac effects of 
orally administered GPC have not yet been reported. Orally 
administered GPC showed several beneficial, non-cardiac 
effects such as neuroprotective effects in different types of 
brain damage [20–22] and mental disorders [23], as well as 
in acute stroke or transient ischemic attacks [7]. It has also 
been shown that GPC can rapidly cross the blood–brain bar-
rier [11]. Applied GPC doses in these studies were relatively 
high. It is important in future in vivo experiments to examine 
the dose–response relationship between GPC and risk organs 
which are different from the target one, with a special empha-
sis on the possible side effects.
Firstly in our study, we assessed the impact of differ-
ent exogenous GPC doses on healthy cardiac myocytes in 
normoxic conditions. Our chosen concentration range of 
GPC (1–100 µM) was based on pilot experiments and on 
papers describing the free choline concentrations in plasma 
[24, 25]. The viability of cells was not influenced by any of 
the applied GPC concentrations in any of the experimental 
setups, except for the 24 h treatment at which time point 
profound superoxide and overall ROS accumulation were 
also detected. Other in vitro studies indicated the emerg-
ing oxidative stress of 24-h GPC administration applied 
on astrocytes [26] and excessive neuronal cell death was 
described in another recent scenario in response to exog-
enous, chronic GPC [27]. It was also reported that in vitro, 
long-term exposure to muscarinic agonists significantly 
reduced the expression of a series of proteins belonging to 
the cytoskeletal structure and led to a complete change in 
the cellular shape. This possibly made the cells more prone 
to be disturbed by inflammatory factors [28]. In our case, 
this latter was likely due to the increasing amount of ROS. 
This was fully supported by our data. Indeed, after 24 h of 
GPC treatment, a significant increase in both the superoxide 
and overall ROS formation was observed at 1 and 100 µM, 
and superoxide level was detected to be significantly higher 
at 80 µM. In line with these results, cellular viability was 
significantly reduced at 1, 80, and 100 µM concentrations, 
respectively. GPC is previously reported to increase inositol 
phosphate (IP) formation and to promote PKC translocation 
in the brain [29]. However (to date), no similar observations 
were obtained in cardiac cells. In fact, it is well known that 
cardiac dysfunction with marked changes in the membrane 
inositol phosphate-Protein Kinase C (IP-PKC)-mediated 
signalization and subsequent  Ca2+-handling abnormalities 
in cardiac myocytes arise primarily from oxidative stress 
as well as reduced antioxidant defenses [30]. It is thus pos-
sible that long-term exposure to a modulator of the IP-PKC 
cascade led to a critical accumulation of ROS with inescap-
able cell death. The possible explanation of the long-term 
cytotoxic effect might also be due to the feature of GPC as 
being a muscarinic acetylcholine receptor (mAChR) ago-
nist [6]. Several mAChR subtypes may be potentially linked 
to the ROS production through multiple effector cascades, 
i.e., by elevating intracellular calcium levels, activating 
PKC, or by increasing the formation of arachidonic acid 
through phospholipase A2 activation [31]. More recently, 
long-term stimulation of ACh production by cigarette smoke 
extract for 4 days was reported to enhance the traditional 
PI3/PKC/PEBP1/Raf-ERK1/2 pathway activation as well 
as the release of pro-inflammatory and oxidative mediators 
in 16HBE cell line in vitro [32]. The existence of different 
subtypes of mAChRs on rat neonatal cardiomyocytes is well 
supported [33].
Additionally, an action of the 80 µM GPC was seen in the 
long-term scenario at which concentration a complete attenu-
ation in the overall ROS formation but not in the superoxide 
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release was detected. Theoretically, this might point out an 
interplay of GPC in physiological ROS formation and car-
diac mitochondria. As previously mentioned, acute treatment 
with 80 and 100 µM GPC increased the oxygen consumption 
rate (OCR) of healthy cardiac myocytes and tendentiously 
increased the superoxide level. The total ROS staining results 
of the short-term scenario match this observation, since a 
significant reduction was seen at 100 µM GPC but regarding 
the superoxide concentrations, changes remained unnoticed. 
Physiological ROS formation and the redox signaling of car-
diac cells through superoxide play an important role to main-
tain the normal function [34]. Additionally, 80–100 µM GPC 
could promote the physiological need of superoxide through 
a direct mitochondrial effect, which was then attenuated at 
the 100 µM GPC through some general ROS-scavenging 
compensatory mechanism as only the overall ROS level but 
not the superoxide quantity was decreased. This action was 
likely to be uncontrolled and therefore exaggerated in the 
case of the long-term GPC treatment, when the 100 µM dose 
was not enough to reverse the deleterious process.
Previous studies have shown that GPC is able to prevent 
oxidative stress and decrease radical production in different 
I/R models, e.g., liver or mesenteric tissue [12–14]. It has 
also been demonstrated that dietary supplementation with 
a mixture of GPC and other four compounds reduced the 
production of ROS in mice brain [35]. At this point in time, 
no myocardial protection effects were investigated related to 
GPC. Therefore, the same concentrations of GPC treatment 
as used in normoxic conditions were applied in a clinically 
relevant I/R model of cardiac myocytes. After SI/R protocol, 
viability assay was performed and showed that 80 µM GPC 
treatment resulted in a significant improvement of cell viabil-
ity after SI/R. This observation suggested that GPC in 80 uM 
concentration was cytoprotective against I/R, likely via facili-
tating some as-of-yet un-described, fine-tuning mechanism 
in ROS-mediated cell signalization/cellular death pathways.
There are some limitations in the present study as this is 
the first study to investigate the effects of a broad concen-
tration range of GPC on cardiac cells. Nevertheless, in vivo 
experiments would certainly supply further information 
regarding the functional cardiac effects of GPC. The mecha-
nisms of action of GPC on cardiac cells are poorly character-
ized, and therefore it should be studied with multiple omics 
technologies in any depth.
In conclusion, in the present study, we have shown for 
the first time that choline donor l-Alpha-GPC (which is 
widely used as a food supplement and generally considered 
as safe for human use) had ambiguous effects on cardiac 
cells. It may be beneficial in short-term administration to 
maintain the physiological balance of ROS production under 
normoxic, healthy conditions and could be also protective 
in I/R conditions, but could, in fact, be cytotoxic if it sur-
rounded the cells for long enough. Besides the duration of 
the treatment, the correct dosage can also be a crucial fac-
tor, as a fine-tuning effect seemed to occur in a small, but 
dietary-relevant concentration range. Thus (despite many 
limitations of this in vitro study), our results indicate the 
need for a comprehensive cardiac safety testing of GPC.
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